Cardio Dx will sponsor a clinical study investigating use of its PrecisionCHD test to identify patients with CHD and assess response to Agepha's low-dose colchicine agent LODOCO.

The acquired antibodies target hormones like thyroid stimulating hormone, human chorionic gonadotropin, prolactin, and total thyroxine.

The test is used for the detection of antibodies against Borrelia burgdorferi in serum from patients with signs, symptoms, and clinical history consistent with Lyme disease.

Investigators compared risk prediction using PathomIQ's platform to molecular test results, evaluating its ability to predict biochemical recurrence in high-risk patients.

Health Canada has allowed the firm to bypass a requirement that tests be authorized for non-professional use prior to self-test authorization.

The Tulane team has developed a handful of other assays for TB detection, including a mass spec test for paucibacillary TB ...

Broader macroeconomic uncertainty has resulted in continued cautiousness for both investors and acquirers in the in vitro ...

NEW YORK – With the recent completion of a multisite study in Europe and the opening of a lab in Tennessee, Glasgow, Scotland-based liquid biopsy developer Dxcover plans to launch its infrared ...

NEW YORK – After months of declining share prices, diagnostics firm got a reprieve in June as the 360 Top 30 rose nearly 6 percent month over month. The Top 30 mirrored the broader markets as the Dow ...

A lab owner, marketing firm owner, and doctor have been sentenced to between 13 months and five years in prison for their roles in a multimillion-dollar lab fraud scheme.

NEW YORK – A federal judge on Tuesday ruled that the US Department of Health and Human Services' March decision to lay off 10,000 staff members as part of a major restructuring was likely unlawful and ...